CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Novo Holdings backs European fund; Alnylam sends second obesity drug into clinic

Trial Startsecond obesity drugPositive
AI Analysis

Summary

Novo Holdings invests €500 million in the Scaleup Europe Fund. Alnylam advances a second obesity drug into clinical development.

Importance:4/10
Sentiment:
0.50
Alnylamobesityclinical developmentNovo Holdingsfund investment
Related Companies

Read the original article

Published by Endpoints News on June 4, 2026 2:48 PM

Read Original